According to the report by MRFR, the kidney biopsy market is projected to record a strong CAGR of over 5.2% during the review period.
Kidney biopsy, also called a renal biopsy, refers to obtaining a sample from kidney tissue for examination. It is used for the diagnosis of kidney disease, monitoring the effect of treatment, and checking the well-functioning of a transplant. The global kidney biopsy market has witnessed massive growth over recent times due to an increase in demand for new techniques for diagnosing chronic diseases and a rising number of biopsy procedures. Furthermore, the rising need for better diagnostic and treatment methods, increasing prevalence of kidney diseases, and consistent technological advancements are also likely to catalyze the market’s growth over the review timeframe. However, the market is likely to be impeded by the high cost of diagnostic services.
Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/5309
The global kidney biopsy market is divided into several segments based on indication, type, end-user, and region.
The kidney biopsy market is split into surgical and percutaneous biopsies based on type.
Based on indication, the global market is divided into kidney transplants, proteinuria, kidney failure, hematuria, and others.
By end-users, the kidney biopsy market is divided into urology centers, tertiary care centers, hospitals & clinics, and others.
The global kidney biopsy market is studied across four major regions, including the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The American regional kidney biopsy market secures the top position across the globe. The regional market’s growth is being driven by the high health care spending, government support for research & development, wide-ranging use of technologically advanced medical devices for diagnosis and treatment of kidney disease, a growing number of patients with kidney disease, diabetes, and other risk factors causing renal failure.
The European region is the second-largest kidney biopsy market across the globe. The regional market’s growth is attributed to the availability of funds for research, rising government support for research & development, rising focus on the development of innovative diagnostic devices in urology, an increasing number of specialty services provided by several healthcare providers. Moreover, the increased application and significant investments and favorable reimbursement policies are also projected to boost the performance of the regional market.
The Asia-Pacific region is projected to record the fastest growth rate over the assessment timeframe attributed to the high healthcare expenditure, rapidly developing healthcare technology sector, rising number of kidney transplant procedures in urology centers, the ever-increasing prevalence of diabetes, and increasing demand for quality devices.
The global kidney biopsy market for the Middle East & African region is projected to acquire the least share over the review timeframe because of the unavailability of technologically advanced medical devices, limited medical facilities, and less availability of funds.
The global kidney biopsy market has a strong and competitive landscape. The players worldwide are fighting to strengthen their market position and grow their customer base. The list of leading players in the kidney biopsy market includes Argon Medical Devices, Inc. (U.S.), Focal Therapeutics, Inc. (U.S.), Integra LifeSciences Corporation (U.S.), Precision Biopsy, LLC (U.S.), Hologic Inc. (U.S.), C R Bard, Inc. (U.S.), Boston Scientific Corporation (U.S.), CareFusion (U.S.), Creganna (U.S.), Scion Medical Technologies LLC (U.S.), Intact Medical Corporation (U.S.), Devicor Medical Products Inc. (U.S.), Cook Medical (U.S.), and many others.
September 2021 – a global leader in cell-free DNA (cfDNA) testing, Natera, Inc., announced the introduction of the only cfDNA test for kidney rejection, Prospera with Quantification that offers three values- total cfDNA, the fraction of dd-cfDNA, and the quantity of donor-derived cfDNA (dd-cfDNA) on every report. Combining these three metrics has been offered to enhance sensitivity when assessing transplant rejection compared to the use of dd-cfDNA fraction alone.
May 2021- a leading clinical-stage gene therapy company targeting free people from a lifetime of genetic disease, AVROBIO, Inc., offered an update on its regulatory plans for AVR-RD-01, the first investigational lentiviral gene therapy for Fabry disease. The update follows the latest U.S. regulatory development for Fabry disease therapies.
Read Complete Report @ https://www.marketresearchfuture.com/reports/kidney-biopsy-market-5309
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have the supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country-level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312